Cleara Biotech

Cleara Biotech is advancing a novel therapeutic paradigm by targeting distinct subtypes of senescent cells, which are drivers of chronic diseases and cancer progression. Its core technology is a FOXO4/p53-based D-amino acid peptide platform, from which it has optimized two lead candidates, CL04177 and CL04183, targeting 'scarred' senescence. The company, founded on seminal academic research from the University Medical Center Utrecht, is led by a team with deep expertise in senescence biology and clinical development, and is preparing its lead programs for clinical trials in solid tumors and hematological malignancies.

A proprietary platform for designing D-amino acid peptide therapeutics that selectively disrupt protein-protein interactions to eliminate specific subtypes of senescent cells, guided by companion diagnostic biomarkers.

Cleara competes with companies developing broad-spectrum senolytics (e.g., Unity Biotechnology). Its key differentiation is a precision medicine approach targeting specific 'scarred' senescence subtypes using a stable D-amino acid peptide platform, aiming for improved safety and efficacy by sparing beneficial senescent cells.